The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal ProductsGloria M. Palomo, Segundo Mariz, Darius Matusevičius et al.|Molecular Therapy|2023Cited by 15
Advancing rare disease treatment: EMA’s decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designationMaria Elisabeth Kalland, Segundo Mariz, Enrico Costa et al.|Gene Therapy|2024Cited by 8